These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 11583303)

  • 41. Inactivation of plasminogen activator inhibitor-1 accelerates thrombolysis of a platelet-rich thrombus in rat mesenteric arterioles.
    Rupin A; Martin F; Vallez MO; Bonhomme E; Verbeuren TJ
    Thromb Haemost; 2001 Dec; 86(6):1528-31. PubMed ID: 11776323
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Present-day thrombolytic therapy: therapeutic agents--pharmacokinetics and pharmacodynamics.
    Bell WR
    Rev Cardiovasc Med; 2002; 3 Suppl 2():S34-44. PubMed ID: 12556741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel and emerging therapies: thrombus-targeted fibrinolysis.
    Lippi G; Mattiuzzi C; Favaloro EJ
    Semin Thromb Hemost; 2013 Feb; 39(1):48-58. PubMed ID: 23034825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombolysis for restoration of patency to haemodialysis central venous catheters: a systematic review.
    Clase CM; Crowther MA; Ingram AJ; Cinà CS
    J Thromb Thrombolysis; 2001 Apr; 11(2):127-36. PubMed ID: 11406727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of transport parameters and enzyme kinetics of the fibrinolytic system on thrombolysis: mathematical modelling of two idealised cases.
    Zidansek A; Blinc A
    Thromb Haemost; 1991 May; 65(5):553-9. PubMed ID: 1831302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model.
    Hashimoto M; Oiwa K; Matsuo O; Ueshima S; Okada K; Okada Y; Okamoto S; Giddings JC; Yamamoto J
    Thromb Haemost; 2003 May; 89(5):820-5. PubMed ID: 12719778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Arterial thrombolysis. Review and future prospects].
    Marzelle J; Combe S; Gigou F; Samama M
    J Mal Vasc; 1988; 13(4):307-16. PubMed ID: 3143794
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thrombolytic treatment with tissue-type plasminogen activator (t-PA) containing liposomes in rabbits: a comparison with free t-PA.
    Heeremans JL; Prevost R; Bekkers ME; Los P; Emeis JJ; Kluft C; Crommelin DJ
    Thromb Haemost; 1995 Mar; 73(3):488-94. PubMed ID: 7667833
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
    Flight SM; Masci PP; Lavin MF; Gaffney PJ
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):417-20. PubMed ID: 16788320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Staphylokinase reduces plasmin formation by endogenous plasminogen activators.
    Jin T; Bokarewa M; Zhu Y; Tarkowski A
    Eur J Haematol; 2008 Jul; 81(1):8-17. PubMed ID: 18331597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ultrasound enhanced thrombolysis in acute arterial ischemia.
    Tsivgoulis G; Culp WC; Alexandrov AV
    Ultrasonics; 2008 Aug; 48(4):303-11. PubMed ID: 18511094
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase 1 study of human plasma-derived plasmin (TAL-05-00018) in hemodialysis graft occlusion.
    Shlansky-Goldberg R
    Thromb Res; 2008; 122 Suppl 3():S16-9. PubMed ID: 18760830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Computer simulation of systemic circulation and clot lysis dynamics during thrombolytic therapy that accounts for inner clot transport and reaction.
    Anand S; Diamond SL
    Circulation; 1996 Aug; 94(4):763-74. PubMed ID: 8772700
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Tissue-type plasminogen activator--a fibrinolytic preparation].
    Makarov VA
    Farmakol Toksikol; 1989; 52(2):90-3. PubMed ID: 2501106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of local thrombolytic efficacy of plasmin and rt-PA in an in-vitro flow system; a pilot study.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Marder VJ; Novokhatny V; Serša I
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):711-4. PubMed ID: 23751605
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A long-lasting, plasmin-activatable thrombin inhibitor aids clot lysis in vitro and does not promote bleeding in vivo.
    Sheffield WP; Eltringham-Smith LJ; Gataiance S; Bhakta V
    Thromb Haemost; 2009 May; 101(5):867-77. PubMed ID: 19404540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence for a role of the plasminogen activator--plasmin system in corneal ulceration.
    Berman M; Leary R; Gage J
    Invest Ophthalmol Vis Sci; 1980 Oct; 19(10):1204-21. PubMed ID: 6252112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.